Advanced Ovarian Cancer: Practical Essentials

Advanced Ovarian Cancer: Practical Essentials

Episodes

Specialty:

All

Year:

All

EP. 1: Adopting Neoadjuvant Therapy into Ovarian Cancer

April 26th 2018

EP. 2: HIPEC in Advanced Ovarian Cancer

April 26th 2018

EP. 3: Upfront Bevacizumab in Advanced Ovarian Cancer

April 26th 2018

EP. 4: Incorporating Bevacizumab into First-Line Practice for EOC

April 26th 2018

EP. 5: Bevacizumab in the Neoadjuvant Setting of EOC

April 26th 2018

EP. 6: Maintenance Therapy in Ovarian Cancer: PARP Inhibitors

April 26th 2018

EP. 7: I-O Therapy in Advanced Ovarian Cancer

April 26th 2018

EP. 8: Biomarkers and Molecular Testing in Ovarian Cancer

April 26th 2018

EP. 9: Approaching Recurrent Ovarian Cancer

April 26th 2018

EP. 10: Bevacizumab in Recurrent Ovarian Cancer

April 26th 2018

EP. 11: Secondary Debulking in Recurrent Ovarian Cancer

April 26th 2018

EP. 12: PARP Inhibitors in Recurrent Ovarian Cancer

April 26th 2018

EP. 13: Additional Considerations: PARPs for EOC in Practice

April 26th 2018

EP. 14: PARP Inhibitor Selection in Ovarian Cancer

April 26th 2018

EP. 15: Sequencing Therapies in Ovarian Cancer

April 26th 2018

EP. 16: Therapy Selection in BRCA-Mutated Ovarian Cancer

April 26th 2018

EP. 17: Managing Ovarian Cancer Patients in the Future

April 26th 2018

Trending on OncLive

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC

Novel Therapies Are Poised to Answer Questions and Reinvigorate Hematologic Oncology at SOHO 2026

Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma